## 1 **Title:** Association of Lung Fibrotic Changes and Cardiological Dysfunction with 2 Hypertension in Long COVID-19 cohort

- 3 Authors
- 4 Ainur Tauekelova<sup>1</sup>, Zhanar Kalila<sup>1</sup>, Bakhtiyar Akerke<sup>1</sup>, Zarina Sautbayeva<sup>2</sup>, Polina Len<sup>2</sup>,
- 5 Aliya Sailybayeva<sup>1</sup>, Sadyk Khamitov<sup>1</sup>, Nazira Kadroldinova<sup>3</sup>, Natalie S. Barteneva<sup>\*2,4</sup> and
- 6 Makhabbat Bekbossynova\*<sup>1</sup>
- 7
- 8 Affiliations
- <sup>9</sup> <sup>1</sup>National Research Center for Cardiac Surgery, Nur-Sultan, Kazakhstan
- <sup>2</sup>School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan
- <sup>3</sup>School of Medicine, Nazarbayev University, Nur-Sultan
- <sup>4</sup>Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States
- 13 \* Corresponding author
- 14

17

- 15 Keywords: LongCOVID-19; post-COVID-19; hypertension; diabetes; ferritin; fibrinogen; lung
- 16 sequelae; cardiovascular sequalae; female gender

## 18 Abstract

Background. Long COVID-19 symptoms appeared in many COVID-19 survivors. However, the prevalence and symptoms associated with long COVID and its comorbidities have not been established

established.

22 Methods. Between May and September 2020, we included 312 patients with post-COVID-19 23 from 21 primary care centers if they had any persistent symptoms for at least three months from 24 the first onset of the disease. On the 6 months follow up, their lung function was assessed by CT 25 and spirometry, whereas cardiac function was assessed by electrocardiogram (ECG). Holter 26 ECG, Echocardiography, and 24-hour blood pressure monitoring. A six-minute test (6MWT) 27 was conducted on 308 participants during the follow-up visit. All participants were given a 28 questionnaire with items on demographic information, current complaints, comorbidities, and 29 medications, and Chalder Fatigue Scale (CFS) questionnaire. Statistical analysis was done using 30 R vs. 4.1.2. Two-group comparison of continuous variables was performed using a T-test for 31 normally distributed data, and the Mann-Whitney Wilcoxon test, ANOVA, and Kruskal-Wallis 32 tests were applied for multiple comparisons following with Tukey and Dunn tests as post-hoc

methods. Hochberg p-value adjustment was used to reduce the false discovery rate during
 multiple comparisons. Categorical variables were analyzed with Fisher's Exact test.

**Results**. Of 312 persons investigated, there was no significant gender difference between post-COVID-19 clinical manifestations except for memory dysfunction and anxiety, more prevalent

among female participants. Chalder Fatigue Score  $\geq 4$  was predominant in female participants

38 (243, 78%). 39 (12.5%) participants reported having type 2 diabetes mellitus, and 158 (50.64%)

- 39 had hypertension.
- 40 Among the tested parameters, those positively correlated with comorbid conditions include age,
- 41 BMI, D-dimers, NT-proBNP, C-reactive protein, neutrophils, fasting glucose, and HbA1c;
- 42 hypertension also shows three associations that were not found in patients when examining the
- 43 role of diabetes: increased hemoglobin, fibrinogen, and ferritin. 24-hour blood pressure 44 monitoring revealed significantly higher systolic and diastolic blood pressure, left ventricular
- 45 hypertrophy, and elevated NT-proBNP in participants with hypertension and subjects with type 2

46 diabetes. Left ventricular diastolic dysfunction is more frequently present in patients with47 hypertension.

48 Chest CT was conducted on 227 (72.8%) participants 5.8±0.9 months after the onset of

49 COVID-19. The most common registered CT abnormality was chronic bronchitis (198, 87.2%),

50 followed by fibrotic changes in (83, 36.6%) and mediastinal lymphadenopathy (23, 10.1%).

51 Immunological test results showed that SARS-CoV19 IgG antibodies were present in 241 52 subjects (77.2%), and SARS-CoV19 IgM antibodies were present in 9 subjects (2.88%).

53 Conclusions. Our study provides valuable clues for long-term post-sequelae in a cohort of the

54 Long COVID-19 subjects. We demonstrated a strong association of signs of cardiac dysfunction,

55 lung fibrotic changes, increased hemoglobin, fibrinogen, and ferritin with hypertension but not

56 with other comorbidities. Our results are of importance for understanding the Long Covid-19

- 57 syndrome.
- 58

## 59 Introduction

60 The COVID-19 disease, resulting from infection with SARS-CoV-2, is highly contagious and may spread asymptomatically or presymptomatically (Furukawa et al., 2020; Rivett et al., 2020; 61 62 Buitrago-Garci et al., 2020). There is a growing concern regarding the potential for COVID-19 63 infection to contribute to a burden of chronic cardiovascular and respiratory symptoms among 64 recovered individuals (Leth et al., 2021). The SARS-CoV2 virus appears unique among 65 coronaviruses due to the high rate of transmission and atypical pattern of inflammatory response 66 leading in severe cases to cytokine storm phenomenon (rev. Tang et al., 2020). Long-COVID-19 67 or post-COVID-19 syndrome describes symptoms lasting for more than three months after the 68 first COVID-19 symptoms onset (Yong, 2021), and there is a critical need to evaluate and 69 understand potential long-term implications of COVID-19. The most frequent symptoms are 70 shortness of breath and fatigue (Cares-Marambio et al., 2021; Shah et al., 2021; Davido et al., 71 2020; Halpin et al., 2020).

72 Many meta-analyses identified that the elderly population with pre-existing disease conditions such as type 2 diabetes mellitus (Singh et al., 2020; Kumar et al., 2020) and hypertension 73 74 (Pranata et al., 2020; de Almeida-Pititto et al., 2021) are found to be at an increased risk of 75 getting COVID-19 infection and its complications (Deng et al., 2020). COVID-19 has been 76 linked to multiple extra-respiratory symptoms more prevalent in patients with positive 77 cardiovascular disease history (Han et al., 2020). Long-lasting alternations in pulmonary 78 function, including the reduced diffusing capacity of lungs and the restrictive syndrome, were 79 observed in patients surviving COVID-19 pneumonia during a 6-month and 12 months follow-up 80 period (Fortini et al., 2021; Fumagalli et al., 2021; Wu et al., 2021; Ordinola Navarro et al., 81 2021). However, long COVID affects even mild-to-moderate cases of survivors of COVID-19 82 with pulmonary sequelae reported after recovery (Wang et al., 2020).

In this paper, we report results from a prospective cohort study of 312 patients with COVID-19 onset between May and September 2020. We are aimed to determine the prevalence and extent of allowing analysis of persisting Long COVID-19 symptoms over 6 months duration emphasizing the patient's cardiovascular and lung sequelae of COVID-19.

87

## 88 2. Materials and Methods

### 89 **2.1 Study design and participants.**

90 This is a prospective cohort study that was based on a pilot project of the post-COVID center 91 in JSC "National Research Cardiac Surgery Center" in Nur-Sultan, Kazakhstan. The study was conducted in December 2020. The post-COVID center was established according to the order of 92 93 the Ministry of Health of the Republic of Kazakhstan No. 763 dated November 24, 2020, as a 94 pilot project for the improvement of the coronavirus infection situation in the healthcare of the 95 country. Participants were referred from the primary care centers of Nur-Sultan (Kazakhstan) to the post-COVID center. Participants were selected if they had any persistent symptoms for at 96 97 least three months from the first onset of the disease. Selected 312 were referred to the follow-up 98 visit to JSC "National Research Cardiac Surgery Center." All participants had confirmed 99 infection with positive PCR during the active infection or laboratory immunohistochemical 100 results. The study was ethically approved according to the order of the Ministry of Health of the 101 Republic of Kazakhstan, and informed consent was taken in the primary care centers.



### 102

103 **Figure 1.** Study flow diagram.

#### 104 2.2 Clinical Assessment

105 All participants were given a questionnaire with items on demographic information, current complaints, comorbidities, and medications (Appendix 1). All participants were given Chalder 106 107 Fatigue Scale (CFS) questionnaire (Appendix 2) for completion. Vital signs of participants, 108 including blood pressure and heart rate were performed by one of three physicians participating 109 in data collection. Venous blood samples were collected from all participants for complete blood 110 count, including hemoglobin, white blood cells, lymphocytes, neutrophils, and platelet count, for 111 biochemistry panel, including serum creatinine, blood urea, total cholesterol, glucose, and ALT, 112 for coagulation profile, including fibrinogen and D-Dimer (DD), and for glycohemoglobin  $A_{1c}$ (HbA1c), C-reactive protein, ferritin, vitamin B12, vitamin 25(OH)D, and NT-proBNP. For 113 114 coagulation tests AVATUBE R with sodium citrate was used, and Sysmex CS-2500 instrument

115 (Sysmex, Japan). Blood for DD was collected in AVATUBE R with sodium citrate, and D-116 dimers quantification was performed with Cobas R 6000. Additionally, blood analysis for 117 immunological tests was performed, including SARS-CoV-2 IgG, SARS-CoV-2 IgM, CMV 118 IgG, and CMV IgM antibodies quantified by ELISA. All participants were proposed chest CT, 119 but 85 participants (28.3%) refused due to personal claims. Cardiac function was assessed by 120 electrocardiogram (ECG), Holter ECG, Echocardiography, and 24-hour blood pressure 121 monitoring in all participants. A six-minute test (6MWT) was conducted in 308 participants at 122 the follow-up visit. The medical records of each participant were reviewed independently by three physicians (cardiologist with more than 10 years of experience) of the hospital. All CT 123 124 images were reviewed in random order by one senior cardiothoracic radiologist who were not 125 aware of any clinical or laboratory findings or participant outcomes. The confirmation of 126 COVID-19 infection was done by RT-PCR assay on nose/throat swab or sputum samples using 127 CFX96 R Real-Time System (Bio-Rad Laboratories, Inc., USA).

128

#### 129 2.3 Statistical Analysis

130 Statistical analysis was performed in parallel using R vs. 4.1.2 (2021-11-01) and GraphPad 131 Prism vs. 8.4.3 (Dotmatics, USA). Normality was assessed using the Shapiro test. Two-group 132 comparison of continuous variables was performed using T-test for normally distributed data and 133 MannWhitney Wilcoxon test if the condition of normality was violated. For multiple 134 comparisons ANOVA and Kruskal-Wallis tests were applied with Tukey and Dunn tests as post-135 hoc methods. Hochberg p-value adjustment was used to reduce the false discovery rate during 136 multiple comparisons. Categorical variables were analyzed with Fisher's Exact test.

137

#### 138 2.4 Role of funding source

139 This research has been funded by the Science Committee of the Ministry of Education and 140 Science of the Republic of Kazakhstan (Grant No. BR10965164). https://www.ncste.kz/en/main. 141 The funders had no role in study design, data collection and analysis, decision to publish, or 142 preparation of the manuscript.

143

#### 144 **2.5 Ethical considerations**

145 All participants of the study provided written informed consent. The study was approved by the 146 National Research Center Cardiac Surgery Center Ethical Committee (#01-97/2021 from 147 22/04/21). No compensation was provided to participants (only reimbursing of travelling costs).

#### 148 **3. Results**

#### 149 **3.1 Cohort description**

150 The comorbidities are reported in **Table 1** from the most prevalent to the least. Overall, 223 151 participants had at least one comorbidity. The most common comorbidities included 152 hypertension (154, 50.6%), gastrointestinal (GI) disorders (74, 23.73%), and neurological 153 disorders (43, 13.78%). Some of the participants also had overlapping of the comorbidities.

154 The proportion of coronary artery disease (CAD) in male participants was higher than in 155 females, 14.85% in males vs. 7.11% in females, P=0.030. Meanwhile, endocrine disorders were 156 more prevalent among female participants (16, 7.58%) vs. 1, 0.99%), respectively, P=0.016).

- 157 Respiratory comorbidities include asthma and chronic obstructive disease (COPD) (9, 2.88%)
- 158 with no significant difference among female and male participants.

## 159

160 **Table 1.** Clinical characteristic and comorbidities in participants after COVID-19 infection.161

|                               | Total        | Female      | Male       | <i>P</i> -value |
|-------------------------------|--------------|-------------|------------|-----------------|
|                               | (n=312)      | (n=211)     | (n=101)    |                 |
| Age <sup>†</sup> ,            | 54 (42.5;60) | 54 (44;60)  | 55 (40;61) | 0.689           |
| years                         |              |             |            |                 |
| BMI <sup>†</sup> ,            | 26.9         | 26.9        | 26.7       | 0.531           |
| kg/m <sup>2</sup>             | (23.4,31.1)  | (25.1,51.0) | (24,30.4)  |                 |
| Obesity class                 |              |             |            |                 |
| Overweight<br>(BMI 25.0–29.9) | 90 (28.9)    | 57 (27.0)   | 33 (32.7)  | 0.302           |
| Obese<br>(BMI ≥30.0)          | 103 (33.0)   | 73 (34.6)   | 30 (29.7)  | 0.390           |
| CFS ≥4                        | 243 (77.9)   | 173 (82.0)  | 70 (69.31) | 0.012           |
| Hypertension                  | 158 (50.6)   | 112 (53.1)  | 61 (60.4)  | 0.224           |
| GI disorders                  | 74 (23.7)    | 49 (23.2)   | 25 (24.7)  | 0.766           |
| Neurological disorders        | 43 (13.8)    | 31 (14.7)   | 12 (11.9)) | 0.500           |
| Type 2 Diabetes               | 40 (12.8)    | 27 (12.8)   | 12 (12.9)  | 0.985           |
| CAD                           | 30 (9.62)    | 15 (7.10)   | 15 (14.9)  | 0.030           |
| Endocrine<br>disorders        | 17 (5.45)    | 16 (7.58)   | 1 (0.99)   | 0.016           |
| Heart Failure                 | 14 (4.49)    | 8 (3.79)    | 6 (5.94)   | 0.391           |
| UTI disorders                 | 14 (4.49)    | 7 (3.32)    | 7 (6.93)   | 0.149           |
| Rhythm<br>disturbances        | 6 (1.92)     | 3 (1.42)    | 3 (1.42)   | 0.157           |
| Asthma                        | 7 (2.24)     | 6 (2.84)    | 1 (0.99)   | 0.301           |
| COPD                          | 2 (0.64)     | 1 (0.47)    | 1 (0.99)   | 0.593           |
|                               |              |             |            |                 |

Note. Except where indicated, data are numbers of participants, with percentages in parentheses. P values comparing female and male participants were determined with the Fisher's Exact test, independent-samples t test, or Mann-Whitney U test.

CFS – Chalder Fatigue Score

GI disorders include chronic cholecystitis, pancreatitis, steatohepatitis, and atrophic gastritis Neurological disorders include encephalopathy of mixed etiology; endocrine disorders include hypothyroidism.

<sup>†</sup>Data are medians, with interquartile ranges in parentheses.

162

163 A total of 312 participants who were previously infected with COVID-19 infection were 164 included in the study. Mean time for the post-COVID-19 assessment was  $5.8 \pm 0.9$  months onset 165 of first symptoms of COVID-19 infection. 111 participants had hospitalization during the active 166 COVID-19 infection while 201 participants were treated at home. Clinical characteristics of the 167 participants are reported in **Table 1**.

Median age of all participants were 54 years (IQR, 17.5) and 211 participants (67.6%) were females. One participant required extracorporeal oxygenation membrane oxygenation (ECMO) during the active infection. Median age of all participants was 54 years (IQR, 17.5) and 211 participants (67.6%) were females. Median BMI of all participants was 26.9 kg/m<sup>2</sup> (IQR, 7.7) with 90 participants (28.9%) overweight and 103 participants (33.0%) obese. Chalder Fatigue

173 Score  $\geq 4$  was present in 243 participants (78%) with more predominance in female participants.

174

## 175 **3.2 Clinical manifestations at the follow-up and laboratory results**

Clinical manifestations of participants at the follow-up are reported in Table 2. The symptoms 176 177 are presented from the most common to the least. The most common symptoms among 312 178 participants were fatigue (220, 70.51%), tiredness (180, 57.69%), and sleep disturbances (168, 179 53.85%), muscle pain (109, 34.9%), memory disfunction (108, 34.9%), dizziness (34.9%), 180 headache (79, 25.3%), instability of blood pressure mostly with increased systolic blood pressure 181 (62, 19.9%), palpitation (47, 15.1%), dyspnea on exertion (45, 14.4%), joint pain (39, 12.5%), 182 and increased sweating (39, 12.5). Overall, there were no significant difference between post-183 COVID-19 clinical manifestations among female and male participants, except memory 184 dysfunction and anxiety. Both were more prevalent among female participants, 81 female 185 participants (38.4%) reported memory dysfunction (27 male participants (26.7%), P=0.043) and 186 28 female participants (12.3%) reported anxiety (2 male participants (1.98%), P=0.003).

**Table 2.** Participants-reported clinical manifestations persistent after COVID-19 infection at
 median of 6 months follow-up.

|              | Total      | Female     | Male      | <i>P</i> -value |
|--------------|------------|------------|-----------|-----------------|
|              | (n=312)    | (n=211)    | (n=101)   |                 |
| Fatigue      | 220 (70.5) | 143 (67.8) | 77 (76.2) | 0.125           |
| Tiredness    | 180 (57.7) | 118 (55.9) | 62 (61.5) | 0.361           |
| sleep        | 168 (53.9) | 116 (55.0) | 52 (51.5) | 0.563           |
| disturbances |            |            |           |                 |
| Muscle       | 109 (34.9) | 78 (37.0)  | 31 (30.7) | 0.277           |
| pain         |            |            |           |                 |

| memory         | 108 (34.6) | 81 (38.4)  | 27 (26.7) | 0.043 |
|----------------|------------|------------|-----------|-------|
| dysfunction    |            |            |           |       |
| dizziness      | 107 (34.3) | 80 (37.9)  | 27 (26.7) | 0.052 |
| headache       | 79 (25.3)  | 59 (28.0)  | 20 (19.8) | 0.121 |
| BP             | 62 (19.9)  | 38 (18.0)  | 24 (23.8) | 0.233 |
| instability    |            |            |           |       |
| Palpitation    | 47 (15.1)  | 34 (16.1)  | 13 (12.9) | 0.454 |
| Dyspnea on     | 45 (14.4)  | 31 (14.7)  | 14 (13.9) | 0.845 |
| exertion       |            |            |           |       |
| joint pain     | 39 (12.5)  | 30 (14.2)  | 9 (8.9)   | 0.185 |
| increased      | 39 (12.5)  | 29 (13.7)  | 10 (9.9)  | 0.337 |
| sweating       |            |            |           |       |
| anxiety        | 28 (8.97)  | 26 (12.32) | 2 (1.98)  | 0.003 |
| hair loss      | 27 (8.65)  | 19 (9.00)  | 8 (7.92)  | 0.750 |
| Dyspnea on     | 18 (5.77)  | 11 (5.21)  | 7 (6.93)  | 0.543 |
| rest           |            |            |           |       |
| decreased      | 18 (5.77)  | 12 (5.69)  | 6 (5.94)  | 0.928 |
| vision         |            |            |           |       |
| GI             | 16 (5.13)  | 12 (5.69)  | 4 (3.96)  | 0.518 |
| symptoms       |            |            |           |       |
| chest pain     | 12 (3.85)  | 11 (5.21)  | 1 (0.99)  | 0.070 |
| in rest        |            |            |           |       |
| Daytime        | 11 (3.53)  | 6 (2.84)   | 5 (4.95)  | 0.563 |
| sleeping       |            |            |           |       |
| Cough with     | 9 (2.88)   | 7 (3.32)   | 2 (1.98)  | 0.509 |
| sputum         |            |            |           |       |
| mood           | 8 (2.56)   | 5 (2.37)   | 3 (2.97)  | 0.753 |
| change         |            |            |           |       |
| chest pain     | 7 (2.24)   | 5 (2.37)   | 2 (1.98)  | 0.828 |
| on exertion    |            |            |           |       |
| dry cough      | 7 (2.24)   | 7 (3.32)   | 0         | 0.064 |
| numbness       | 7 (2.24)   | 5 (2.37)   | 2 (1.98)  | 0.828 |
| in extremity   |            |            |           |       |
| decreased      | 6 (1.92)   | 6 (2.84)   | 0         | 0.087 |
| hearing        |            |            |           |       |
| tremor in      | 5 (1.60)   | 3 (1.42)   | 2 (1.98)  | 0.713 |
| extremity      |            |            |           |       |
| Impaired       | 5 (1.60)   | 3 (1.42)   | 2 (1.98)  | 0.713 |
| sense of smell |            |            |           |       |
|                |            |            |           |       |
| increased      | 4 (1.28)   | 3 (1.42)   | 1 (0.99)  | 0.751 |
| weight         |            |            |           |       |
| decreased      | 3 (0.96)   | 2 (0.95)   | 1 (0.99)  | 0.971 |
| concentration  |            |            |           |       |
| Wheezing       | 2 (0.67)   | 1 (0.47)   | 1 (0.99)  | 0.593 |

| nervousnes     | 2 (0.64) | 2 (0.95) | 0        | 0.326 |
|----------------|----------|----------|----------|-------|
| S              |          |          |          |       |
| presyncope     | 2 (0.64) | 2 (0.95) | 0        | 0.326 |
| syncope        | 2 (0.64) | 2 (0.95) | 0        | 0.593 |
| Impaired       | 2 (0.64) | 1 (0.47) | 1 (0.99) | 0.593 |
| sense of taste |          |          |          |       |
| fever          | 2 (0.64) | 1 (0.47) | 1 (0.99) | 0.593 |
| edema of       | 2 (0.64) | 2 (0.95) | 0        | 0.326 |
| extremities    |          |          |          |       |
|                |          |          |          |       |

Note.— Data are numbers of participants, with percentages in parentheses. P values comparing female and male participants were determined with the  $x^2$  test. BP – blood pressure

189

190 Out of 312 participants, 148 (47.44%) had neither hypertension nor type 2 diabetes mellitus, 33 191 (10.58%) had both hypertension and diabetes, 125 (40.06%) had hypertension only, and 6 192 (1.92%) participants had diabetes only. Overall, 39 (12.5%) participants reported having type 2 193 diabetes mellitus, and 158 (50.64%) had hypertension. Among the tested parameters, those 194 positively correlated with comorbid conditions include age, BMI, D-dimers, NT-proBNP, C-195 reactive protein, neutrophils, fasting glucose, and HbA1c; hypertension also shows three 196 associations that were not found in patients when examining the role of diabetes: increased 197 hemoglobin, fibrinogen, and ferritin (Figures 2-4).

Multiple group comparisons had shown that from the parameters highlighted above, older age, higher body mass index, increased D-dimers, and NT-proBNP are primarily correlated with hypertension rather than diabetes mellitus. On the other hand, higher levels of fasting glucose, HbA1c, and C-reactive protein are attributed to having both comorbid states rather than one.

Neutrophils, white blood cells, NT-pro BNP, hemoglobin, and fibrinogen were not significantly different among groups, according to the post-hoc test.

204



206 207 Figure 2. Clinical characteristics and laboratory results of blood samples in post-COVID-19 patients with and without type 2 diabetes: age, D-dimers (DD), ventricular natriuretic peptide 208 209 (NT-proBNP), C-reactive protein (CRP), body mass index (BMI), neutrophils, fasting glucose and glycated hemoglobin (HbA1c) (\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*p < 0.001). 210

- 211
- 212



213 214







Figure 4. Clinical characteristics and laboratory results of blood samples in post-COVD-19 patients with no comorbidities (green), hypertension only (blue), type 2 diabetes mellitus only (orange) and both hypertension and type 2 diabetes (red): age, BMI, NT-proBNP, CRP, neutrophils, WBC, DD, fasting glucose, HbA1c, HGB, fibrinogen and ferritin (\*\*p < 0.01, \*\*\*p< 0.001, \*\*\*\*p < 0.0001).

226

#### 227 **3.3 Lung Function Screening**

228 **Chest CT.** At the follow-up visit with mean of 5.8±0.9 months chest CT was conducted in 227 229 subjects (72.8%). All the chest CT findings are reported in Table 4 from the most common to the 230 least common findings, 12 subjects (5.29%) had normal chest CT. The most common registered 231 CT abnormality was chronic bronchitis in (198, 87.2%) followed by fibrotic changes in (83, 232 36.6%) and mediastinal lymphadenopathy in (23, 10.1%). Most of the participants had more than 233 one CT changes. Median age of participants with lung abnormalities in chest CT was 55 years of 234 age (IQR, 7). on 227 (72.8%) participants. Other CT abnormalities included polysegmental pneumonia, bronchiectasis, emphysema, bullous changes, atelectasis, and interstitial pneumonia 235 236 (Appendix 3). These chest CT findings do not have a comorbidity-associate predisposition. However, fibrotic changes were found in 55 out of 158 patients with hypertension in comparison 237 238 to 30 out of 154 participants without hypertension. (Figure 5A).

Overall, 107 participants had chest CT during active COVID-19 infection, with the mean
percentage of lung defects 36.5±22.6%. Among those participants, 87 subjects (39.6%)
underwent chest CT at the follow-up, and 84 (96.6%) subjects had residual lung abnormalities
detected at the follow-up.



### 243



<sup>245</sup> Figure 5. Fibrotic changes in CT scan of post-COVID-19 patients with hypertension (A).

<sup>246</sup> Cardiac abnormalities in post-COVID-19 patients with and without hypertension (**B**); with and 247 without type 2 diabetes (**C**). (\*p < 0.05, \*\*\*p < 0.001, \*\*\*\*p < 0.0001).

### 248

249 **Spirometry test.** All participants had spirometry test at the follow-up visit and 143 subjects 250 (45.8%) had spirometry without abnormalities. From 169 subjects (54.2%) with abnormal 251 spirometry 118 subjects (37.8%) had restrictive pattern and 43 subjects (13.8%) had mixed 252 results with mostly restrictive pattern. Only 8 subjects (2.6%) had obstructive defects detected in 253 spirometry. Regarding participants with respiratory comorbidities (9), there were 1 participant 254 with restrictive, 1 participant with obstructive, and 4 participants with mixed with mostly 255 restrictive defects. 67 participants (60.3%) out of 111 hospitalized participants had abnormal 256 spirometry results.

Correlation between chest radiographs and 6MWT with lung function. 125 (58.1%) out of
 subjects with abnormal chest CT at the follow-up had abnormalities in spirometry test. 89
 subjects (71.2%) had restrictive pattern, 30 subjects (24%) had mixed with mostly restrictive
 pattern, while 6 subjects (4.8%) had obstructive pattern in spirometry.

The median 6MWT in participants with abnormal spirometry was 381 (310;416) meters, significantly different from participants with normal spirometry (400 (350;450) meters, P =0.004). 14 subjects (77.8%) out of 18 subjects with specific respiratory symptoms, including wheezing, dry cough, and cough with sputum, had abnormalities in chest CT at the follow-up. Meanwhile, 32 (68.9%) out of 45 subjects with dyspnea on exertion and 15 (83.3%) out of 18 subjects with dyspnea on rest had abnormal chest CT scan.

267

### 268 **3.4 Cardiac screening**

269 All 312 participants underwent a cardiac screening (Table 3). Sinus bradycardia <50bpm was 270 present in 4 participants (1.28%). 37 participants (11.9%) had higher NT-pro BNP levels (> 271 125pg/ml) and left ventricular ejection fraction was decreased in 50 participants (1.60%). The 272 most common cardiac abnormality was decreased diastolic function of the left ventricle (122, 273 39.1%). Left ventricular hypertrophy was present in all those participants. 50 (15.5%) had left 274 ventricular hypertrophy, and 40 of them had preexisting hypertension. Meanwhile, 9 participants 275 (18%) out of 50 with left ventricular hypertrophy did not have any cardiovascular comorbidities 276 before the follow-up. Seven participants of those had left ventricular hypertrophy and diastolic 277 dysfunction of LV, while 2 participants had dilatation of the left atrium in addition to left 278 ventricular hypertrophy and diastolic dysfunction.

Holter ECG revealed heart rhythm disturbances in 9 participants for the first time (2.88%), including atrial fibrillation (4, 1.28%), AB block II degree (3, 0.96%), SA block (1, 0.32%), and

RBBB (1, 0.32%). The median age of patients with the first onset of rhythm disturbances was 69

years (IQR, 12), and no difference in gender was found. 2 patients with new-onset AF had

preexisting hypertension, and one patient had newly reported hypertension at the follow-up.

The mean systolic blood pressure (SBP) of all participants was 120.7±16. mm Hg, and the mean

285 diastolic blood pressure (DBP) was 78.4±9.03mmHg with no significant difference between

females and males. Participants with elevated sBP defined as ≥140 mmHg were present in 71
subjects (22.8%).

288 24-hour blood pressure monitoring revealed 19 patients (6.10%) with elevated blood pressure

289 either in the daytime or nighttime for the first time. The median age of participants with new-

290 onset hypertension was 45 years (IQR, 12). One participant was pregnant during the screening,

and none of the patients had cardiovascular conditions before the follow-up time. Two patients

- had type 2 diabetes. One patient had LV hypertrophy, 7 had diastolic dysfunction of LV, one
- 293 patient had dilation of RA, and one patient was with dilation with LA.
- 294

**Table 3.** Cardiac abnormalities detected in cardiac assessment of post-COVID-19 patients.

| Serum cardiac biomarker   | Total        |                 |  |  |
|---|--------------|-----------------|--|--|
| NT-proBNP > 125pg/ml  | 37 (11.9)    |                 |  |  |
|   |              |                 |  |  |
|   | 1            |                 |  |  |
| Electrocardiography   |              |                 |  |  |
| Sinua handwaandia (60hmm  | 26 (9.22)    |                 |  |  |
| Sinus bradycardia < 50bpm   | 20(0.55)     |                 |  |  |
|   | 4 (1.20)     |                 |  |  |
|   | Total        | Newly diagnosed |  |  |
| Echocardiography  |              |                 |  |  |
| Left ventricular ejection   | 61±4.55      |                 |  |  |
| fraction <sup>†</sup> . %   |              |                 |  |  |
| Left ventricular ejection   | 5 (1.60)     |                 |  |  |
| fraction <50%   |              |                 |  |  |
| Left ventricular hypertrophy  | 50 (15.5)    | 7 (2.24)        |  |  |
| Diastolic dysfunction of left   | 122 (39.1)   | 2 (0.64)        |  |  |
| ventricle   |              |                 |  |  |
| Dilation of right atrium  | 2 (0.64)     | 1 (0.32)        |  |  |
| Dilation of left atrium   | 12 (3.85)    |                 |  |  |
|   | [            | 1               |  |  |
| Holter electrocardiography  |              |                 |  |  |
| Atrial Fibrillation   | 5 (1.60)     | 4 (1.28)        |  |  |
| AV block II degree  | 4 (0.32)     | 3 (0.96)        |  |  |
| Sinoatrial block  | 1 (0.32)     | 1 (0.32)        |  |  |
| RBBB  | 1 (0.32)     | 1 (0.32)        |  |  |
|   |              |                 |  |  |
| 24-hr BPM   |              |                 |  |  |
| Mean SBP ≥140mmHg   | 71 (22.8)    | 19 (6.10)       |  |  |
| Mean DBP ≥90 mm Hg  | 49 (15.7)    | 19 (6.10)       |  |  |
| Note. – Except where indicated, data are numbers of participants, with percentages in |              |                 |  |  |
| parentheses.  | a manitarina |                 |  |  |
| * data are means + standard deviation   | e monitoring |                 |  |  |
| data are means $\pm$ standard deviation   |              |                 |  |  |

296

297 Cardiac abnormalities in patients with hypertension and diabetes type 2 compared to 298 participants with no comorbidities are shown in **Figure 5B** and **5C** respectively. 24-hour blood 299 pressure monitoring revealed significantly higher systolic and diastolic blood pressure, left 300 ventricular hypertrophy and elevated NT-proBNP in participants with hypertension and subjects 301 with type 2 diabetes. Left ventricular diastolic dysfunction more frequently present in patients 302 with hypertension.

303

**Laboratory results.** The results of blood laboratory analysis at the follow-up are reported in **Table 4** and **Figures 2-4**. The minority of subjects had persistent inflammatory markers at the follow-up, including neutrophilia in 18 subjects (5.77%) and increased CRP levels in 54 subjects (17.3%). 28 subjects (8.97%) had leukopenia with WBC < 4x109/1 and 13 subjects (4.17%) had lymphopenia with lymphocytes<1.18x 103/1.

309 Immunological test results showed that SARS-CoV19 IgM antibodies were present in 9 subjects

310 (2.88%). Among those, 5 participants had follow-up at 5th months after the onset of the disease,

311 while the other 4 participants had follow-up at 6th months. SARS-CoV19 IgG antibodies were

312 present in 241 subjects (77.2%) and were <10 AH/ml in 71 participants (22.8%). Meanwhile,

313 increased CMV IgG titers defined as >0.5 U/ml were present in almost all 312 participants.

314

**Table 4.** Laboratory results of blood sample in participants after COVID-19 infection with median follow-up of 6 months.

|                        | Normal      | Total            |             | Female           | Male        | <i>P</i> -value |
|------------------------|-------------|------------------|-------------|------------------|-------------|-----------------|
|                        | range       | (n=312)          | )           | (n=211)          | (n=101)     |                 |
|                        |             | Media<br>n (IQR) | n (%)       | -                |             |                 |
| WBC                    | 4.5 - 11    | 5.73             |             | 5.68             | 5.84        | 0.354           |
| (x 10 <sup>9</sup> /l) |             | (6.67;4.85)      |             | (4.71;6.74)      | (5.1;6.52)  |                 |
| <4                     |             |                  |             |                  |             |                 |
| 4-11                   |             |                  | 28 (8.97)   |                  |             |                 |
| >11                    |             |                  | 282 (90.38) |                  |             |                 |
| NEUT                   | 1 56 5 38   | 3 1 1            | 2 (0.04)    | 3.1              | 3 1 1       | 0.762           |
| $(x \ 10^3/l)$         | 1.50 - 5.58 | (2.49:3.9)       |             | (2,43;3,92)      | (2.55;3.73) | 0.702           |
| (1110 /1)              |             | (2.13,513)       |             | (2:10,0:)2)      | (2.00,0.70) |                 |
| <1.56                  |             |                  |             |                  |             |                 |
| 1.56-5.38              |             |                  | 5 (1.60)    |                  |             |                 |
| >5.38                  |             |                  | 289 (92.6)  |                  |             |                 |
|                        | 1 10 2 57   | 1.0              | 18 (5.77)   | 1.0              | 1.05        | 0.076           |
| LYMPH                  | 1.18 - 3.57 | 1.9              |             | 1.9              | 1.95        | 0.276           |
| (X 10 /1)              |             | (1.02,2.28)      |             | (1.30,2.28)      | (1.71,2.20) |                 |
| <1.18                  |             |                  |             |                  |             |                 |
| 1.18-3.57              |             |                  |             |                  |             |                 |
| >3.57                  |             |                  | 13 (4.17)   |                  |             |                 |
|                        |             |                  | 291 (93.3)  |                  |             |                 |
| HOD                    | 100 100     | 104              | 8 (2.56)    | 100              | 1.40        | 0.000           |
| HGB                    | 120 - 160   | 134              |             | 129<br>(122,125) | 148         | 0.000           |
| (g/1)                  |             | (120,143)        |             | (123,133)        | (141,133)   |                 |
| <120                   |             |                  | 34 (10.9)   |                  |             |                 |
| PLT                    | 140 - 400   | 265              |             | 271              | 254         | 0.006           |
| $(x \ 10^{-1})$        |             | (314;230)        |             | (236;327)        | (219;296)   |                 |
|                        |             |                  |             |                  |             |                 |

| <140          |             |             |                        |              |             |       |
|---------------|-------------|-------------|------------------------|--------------|-------------|-------|
| 140-400       |             |             | 9 (2.88)               |              |             |       |
| >400          |             |             | 288 (92.3)             |              |             |       |
|               |             |             | 15 (4.81)              |              |             |       |
| CRP           | 0 - 0.5     | 0.19        |                        | 0.19         | 0.18        | 0.509 |
| (mg/dl)       |             | (0.09;0.41) |                        | (0.08;0.48)  | (0.09;0.34) |       |
|               |             |             |                        |              |             |       |
| >0.5          |             |             |                        |              |             |       |
|               |             |             | 54 (17.3)              |              |             |       |
| Creatinine    | 0.67 - 1.17 | 0.81        |                        | 0.75         | 0.96        | 0.000 |
| (mg/dl)       |             | (0.71;0.94) |                        | (0.68;0.84)  | (0.86;1.08) |       |
|               |             |             |                        |              |             |       |
| <0.67         |             |             | 50 (16.0)              |              |             |       |
| 0.67-1.17     |             |             | 250 (80.1)             |              |             |       |
| >1.17         |             |             | 12 (3.85)              |              |             |       |
| ALT           | 0 - 50      | 18.9        |                        | 17.63        | 20.35       | 0.018 |
| (U/l)         |             | (12.2;26.9) |                        | (12.0;24.6)  | (13.9;33.7) |       |
|               |             |             |                        |              |             |       |
| ≤50           |             |             | 287 (91.9)             |              |             |       |
| >50           |             |             | 25 (8.01)              |              |             |       |
| Glucose       | 74 - 106    |             |                        | 92           | 94          | 0.213 |
| (mg/dl)       |             |             |                        | (84.2;101.4) | (86.4;105)  |       |
|               |             |             |                        |              |             |       |
| <74           |             |             | 10 (3.21)              |              |             |       |
| 74-106        |             |             | 234 (75.00)            |              |             |       |
| >106          |             |             | 68 (21.8)              |              |             |       |
| Ferritin      | 30 - 400    | 82.9        |                        | 62           | 148.7       | 0.000 |
| (ug/l)        |             | (35.3;156)  |                        | (20.8;107)   | (86.7;222)  |       |
| 20            |             |             | 72 (22.1)              |              |             |       |
| <30           |             |             | 72 (23.1)              |              |             |       |
| 30-400        |             |             | 228 (73.1)             |              |             |       |
| >400          | 2 2 0 2     | 2.40        | 12 (3.85)              | 2.54         | 2.24        | 0.110 |
| Fibrin        | 2 - 3.93    | 3.49        |                        | 3.56         | 3.34        | 0.112 |
| ogen          |             | (2.99;4.04) |                        | (3.02;4.04)  | (2.82;4.04) |       |
| (g/1)         |             |             |                        |              |             |       |
| -2            |             |             | 2(0.06)                |              |             |       |
|               |             |             | 3 (0.90)<br>220 (70 5) |              |             |       |
| 2-3.93        |             |             | 220(70.3)              |              |             |       |
| >3.93         | 0 0 50      | 0.22        | 89 (28.3)              | 0.25         | 0.10        | 0.017 |
| D-<br>dimer   | 0-0.50      | (0.23)      |                        | (0.23)       | (0.19)      | 0.017 |
| (mg/l)        |             | (0.19,0.30) |                        | (0.19,0.37)  | (0.19,0.31) |       |
| (111g/1)      |             |             |                        |              |             |       |
| 0_0 50        |             |             | 269 (86 2)             |              |             |       |
| <u>\</u> 0.50 |             |             | 43(13.8)               |              |             |       |
| Urea          | 17-43       | 29.5        | 13 (13.0)              | 30           | 29.2        | 0.301 |
| Ulta          | 1/-+5       | 47.5        | 1                      | 50           | 27.2        | 0.501 |

| (mg/dl)         |         | (24.1;36)       |                    | (24.5;36.2)         | (23.8;35.1)    |            |
|-----------------|---------|-----------------|--------------------|---------------------|----------------|------------|
| >43             |         |                 | 22 (7.05)          |                     |                |            |
| Vitamin         | 182-820 | 475.1           | 22 (1.03)          | 493.3               | 418            | 0.021      |
| B12             | 102 020 | (348:602)       |                    | (368.3:621.9)       | (312.9:563)    | 0.021      |
| (pg/ml)         |         | (510,002)       |                    | (000.0,021.))       | (0121),000)    |            |
| (18,)           |         |                 |                    |                     |                |            |
| <182            |         |                 |                    |                     |                |            |
| 182-820         |         |                 | 24 (7.69)          |                     |                |            |
| >820            |         |                 | 252 (80.8)         |                     |                |            |
|                 |         |                 | 36 (11.6)          |                     |                |            |
| Vitamin D       | 30-100  | 18.33           |                    | 20.3                | 15.7           | 0.024      |
| (ng/ml)         |         | (11.1;30.6)     |                    | (11.5;32.2)         | (10.1;28.4)    |            |
|                 |         |                 |                    |                     |                |            |
| <30             |         |                 | 232 (74.4)         |                     |                |            |
| ≥30             |         |                 | 80 (25.6)          |                     |                |            |
| Hb1Ac           | 4.8-5.9 | 5.4             |                    | 5.3                 | 5.5            | 0.032      |
| (%)             |         | (5.1;5.7)       |                    | (5;5.7)             | (5.15;5.85)    |            |
|                 |         |                 |                    |                     |                |            |
| >5.9            |         |                 | 59 (18.9)          |                     |                |            |
| Total           | <5.2    | 4.89            |                    | 4.90                | 4.87           | 0.442      |
| cholesterol     |         | (4.29;5.52)     |                    | (4.31;5.63)         | (4.17;5.38)    |            |
| (mmol/l)        |         |                 |                    |                     |                |            |
|                 |         |                 |                    |                     |                |            |
| >5.2            |         |                 | 100 (32.1)         |                     |                |            |
| SARS            | 0.10    | 0.54            |                    | 0.61                | 0.48           | 0.036      |
| COV IgM         | 0-10    | (0.35;1.18)     |                    | (0.36;1.21)         | (0.30;1.07)    |            |
| > 10            |         |                 | 0 (2.99)           |                     |                |            |
| >10             |         | 24.20           | 9 (2.88)           | 24.6                | 21.1           | 0.971      |
| SARS<br>CoV IgC | 0.10    | 34.39           |                    | 34.0                | 31.1           | 0.871      |
|                 | 0-10    | (12.3,00.1)     |                    | (12.2,03.1)         | (15.1,08.0)    |            |
| (AII/<br>ml)    |         |                 |                    |                     |                |            |
| ····)           |         |                 | 71 (22.8)          |                     |                |            |
| CMV             | 0-0.7   | 0.16            | 71 (22.0)          | 0.17                | 0.15           | 0.090      |
| IoM             | 0-0.7   | (0.10)          |                    | (0.14.0.25)         | (0.13)         | 0.070      |
| (COI)           |         | (0.14,0.25)     |                    | (0.14,0.23)         | (0.14,0.17)    |            |
|                 |         |                 |                    |                     |                |            |
| >0.7            |         |                 | 14 (4.49)          |                     |                |            |
| CMV             | 0-0.5   | 490             |                    | 500                 | 446            | 0.142      |
| IgG             |         | (233;500)       |                    | (277;500)           | (183;500)      |            |
| (U/ml)          |         |                 |                    |                     |                |            |
|                 |         |                 |                    |                     |                |            |
| >0.5            |         |                 | 308 (99.0)         |                     |                |            |
|                 | ) 1     | na famala and m | ala participanta u | ure determined with | the Monn White | av II tost |

WBC – white blood cells NEUT – neutrophils LYMPH – lymphocytes HGB – hemoglobin PLT – platelets ESR – erythrocyte sedimentation rate CRP – C-reactive protein

#### 317

### 318 **4. Discussion**

319 In our study 6 months after acute illness with COVID-19, most of patients still meet the criteria 320 for long COVID-19 and show at least one persistent symptom. These results are mainly in line 321 with studies reporting the prevalence of long COVID-19 in patients 3 to 6 months after COVID-322 19 (Al-Aly et al., 2021; Huang C et al., 2021; Nasserie et al., 2021; Nehme et al., 2021). Long-323 Covid-19 symptoms have similarities with chronic fatigue syndrome developed after viral 324 infections (Holmes et al., 1988; Hickie et al., 2006) and may afflict a wide range of organs, with 325 the most common symptoms being chronic fatigue, shortness of breath, cognitive impairments 326 (Cares-Marambio et al., 2021; Shah et al., 2021; Davido et al., 2020; Halpin et al., 2020).

327 The pathophysiology of long COVID-19 respiratory and multi-organ sequelae has a 328 fundamental knowledge gap that must be addressed (Lerner et al., 2021). Viral infections are 329 considered to be cofactors for the initiation and exacerbation of lung fibrosis (Naik, Moore, 330 2010), and clinical evidence suggesting cardiovascular involvement has been reported for 331 essentially all known viral infections (Abelmann, 1971). Observational studies revealed a high 332 percentage of post-COVID-19 sequelae such as respiratory problems, lung fibrosis (Lechowicz 333 et al., 2020; Ali et al., 2021), and cardiovascular problems (Bose, McCarthy, 2020). Moreover, 334 long COVID-19 affects even mild-to-moderate cases of survivors of COVID-19 with pulmonary 335 sequelae reported after recovery (Wang et al., 2020). Secondly, our study demonstrated that 336 deranged blood indices (increased neutrophils, WBC, changed coagulation profile-significantly 337 increased DD; fasting glucose, HbA1c, HGB) and raised inflammatory marker (CRP) are 338 associated with pre-existing comorbidities, specifically, hypertension and diabetes. HbA1c is 339 considered the gold standard for evaluating blood glucose levels (Nalysnyk et al., 2010) and is 340 considered to be associated with inflammation, hypercoagulability, blood oxygen saturation, and 341 higher mortality rate in COVID-19 patients (Wang et al., 2020).

342 Hypertension affects more than a quarter of the global population (Kearney et al., 2005; 343 Forouzanfar et al., 2017), has been identified as a major risk factor for COVID-19 severity 344 (Liang et al., 2020; Madhur et al., 2021) and higher risk of dying from COVID-19 (Gao et al., 345 2020). Moreover, hypertension is closely associated with other comorbidities, predominantly 346 obesity and diabetes, and significantly affects inflammation (Jayedi et al., 2019). In this study, 347 hypertension, besides the above-mentioned significant changes in blood and inflammatory 348 markers that coincided with other comorbidities (diabetes), also revealed significant changes in fibrinogen (Fbg) and ferritin levels. Changes in Fbg levels can be associated with a substantial 349 350 rearrangement in blood vessel walls observed in individuals with pre-existing hypertension. The 351 abnormal Fbg levels have a strong association to COVID-19 disease severity (rev. Len et al., 352 2022), and assessment of Fbg levels at admission is important for determining of prognosis of 353 COVID-19 patients (Long et al., 2021). Abnormal Fbg levels are observed in post-COVID-19 354 cohorts by different groups (Tartari et al., 2021). Cardiovascular changes associated with

355 COVID-19 may lead to left ventricular dysfunction (Medranda et al., 2021), which in our cohort
 had a higher prevalence in convalescent patients with hypertension.

357 Cardiac screening showed a mean ejection fraction  $61\pm4.55\%$ , which is less than in 358 participants observed 1-4 weeks after discharge (Zhou, 2021). This can be explained by a higher 359 prevalence of chronic heart diseases, including hypertension and CAD, in our cohort of 360 participants. Interestingly, our study revealed new cases of left ventricular hypertrophy and 361 diastolic dysfunction of LV in participants with no preexisting cardiovascular disorders. In 362 addition, 19 participants had newly diagnosed hypertension during the follow-up. The patients 363 with newly diagnosed hypertension were young (median, 45 years) and had no preexisting 364 cardiovascular comorbidities before the follow-up. However, echocardiography revealed long-365 term complications in some of those patients, meaning that hypertension might have been before 366 the 6-month follow-up and COVID-19 infection. In addition to hypertension and LV 367 dysfunction, our study found 9 new cases of rhythm disturbances detected in 24-hour BP 368 monitoring. Newly detected rhythm disturbances included atrial fibrillation (AF), AB block II 369 degree, sinoatrial (SA) block, and RBBB (Table 3).

370 Although our cohort was limited to establishing the time of the onset of hypertension in the 371 post-COVID-19 period, our findings in patients with no preexisting cardiac comorbidities and 372 standard echocardiography suggest the presence of the long-term effect of COVID-19 on cardiac 373 function. The evidence of cardiac injury in post-COVID-19 patients (left ventricular ejection 374 fraction and diastolic dysfunction) and the appearance of arrhythmias corroborate with the 375 findings of other investigators (rev. Satterfield et al., 2022; Tudoran et al., 2022). The 376 arrhythmias in post-COVID patients were found to be associated with COVID-19 disease 377 severity (Mohammad et al., 2021).

In patients with COVID-19, the viral infection may initiate inflammation with subsequent fibrosis, and cardiac inflammation and fibrosis are major pathological mechanisms leading to heart failure (Suthahar et al., 2017). Non-invasive imaging, blood analysis for fibrosis markers, and endomyocardial biopsy (EMB) are used to detect fibrosis (Raafs et al., 2021). The primary imaging technique in contemporary heart failure management is echocardiography; however, it provides little information about the extent of fibrosis (de Boer et al., 2019). To evaluate the cardiac and lung changes we used echocardiography and the chest CT.

385 The question if the lung is a target organ for diabetes mellitus has been discussed, and a body 386 of clinical and experimental evidence indicates that fibrosis and other pulmonary complications 387 are more prevalent than it was early recognized (Sandler, 1990; Hsia, Raskin, 2005; Yang et al., 388 2011). Critically fibrotic changes on follow-up CT scans were significantly associated with 389 hypertension but not diabetes (Figure 5). The presence of diabetes and new-onset diabetes was 390 an independent factor associated with poor outcomes during different coronavirus infections – 391 SARS-CoV-1 (Yang et al., 2006), MERS-CoV (Alraddadi et al., 2016), and SARS-CoV-2 (rev. 392 Singh, Singh, 2020). In our study, hypertension had a significant association with fibrotic 393 changes on CT-scan, whereas diabetes type II did not. One of the possible explanations can be a 394 small percentage of patients with diabetes type II in our Long COVID-19 cohort. However, we 395 may also speculate that the fibrotic changes in post-COVID-19 develop faster when blood 396 vessels are already affected by hypertension. It was reported that abnormal lung CT findings 397 could present even in asymptomatic or mild COVID-19 patients (Shi et al., 2020). The 398 association of radiological CT findings with hypertension in Long COVID-19 makes 399 hypertension, in combination with other results (high fibrinogen, DD, etc.), a possible early 400 marker of developing fibrotic lung changes.

401 Laboratory tests identified the long-term persistence of IgM antibodies in 9 patients from our 402 cohort (5-6 months). The IgM antibodies at COVID-19 infection peak early and rapidly decline (rev. Huang AT et al., 2020; Mallon et al., 2021; Štěpánek et al., 2022). IgM seropositivity was 403 404 found to be correlating with a symptom duration (Stěpánek et al., 2022). Moreover, the long-405 term persistence of anti-SARS-CoV-2 IgM antibodies was recently reported by Bichara and 406 colleagues (2021), who observed a long 8-months persistence of the IgM antibodies after 407 COVID-19 infection in two patients. The prolonged persistence of anti-viral IgM antibodies was 408 described after different acute viral infections and live viral vaccines: the Japanese encephalitis 409 live vaccine (Hills et al., 2021), acute hepatitis A infection (Kao et al., 1984), dengue virus 410 infection (Chien et al., 2018), Zika virus > 2 years (Griffin et al. 2019), yellow fever virus 411 vaccine > 3-4 years (Gibney et al., 2012), and in cerebrospinal liquid and blood of patients after 412 West Nile virus infection (Kapoora et al., 2004; Roehrig et al., 2003; Papa et al., 2011; Murray et 413 al., 2013) in some cases up to 8 years after infection. The finding of long persistence of IgM 414 antibodies in some participants of the post-COVID-19 cohort warrants additional investigation, 415 particularly the determination of whether persistence of IgM is related to persistent infection 416 with SARS-CoV2. However, the finding of elevated IgG anti-CMV antibodies in most of the 417 cohort should be interpreted with caution due to the possibility of cross-reactivity between viral 418 epitopes and human tissue antigens (Kreye et al., 2020; Vojdani et al., 2021).

419 According to Chalder Fatigue Score, the prevalence of some symptoms, as well as 420 neurological symptoms had a significant association with the female gender. This finding 421 corroborates the recent conclusions of another prospective study of Long COVID-19 syndrome 422 (Bai et al., 2022).

423 There are several limitations of our study: (1) Patients only with persistent symptoms were 424 selected for the study, and there was no control group for comparison of patients with and 425 without the Long COVID-19 syndrome; (2) The absence of baseline health data and CT-imaging 426 data before the infection and before the mean of 6 months of follow-up limits the assessment of 427 changes in patient's results; (3) Social information of patients, including the number of years of 428 smoking, alcohol use, and lifestyle, was not reported, which might have a confounding effect on 429 some of the results. We did not include in the asymptomatic cohort individuals with a mild 430 phenotype of disease though non-hospitalized subjects with moderate post-COVID-19 were 431 included; (4) We had some limitations on cardiovascular measures. It would not be appropriate 432 or feasible to obtain histological data from otherwise healthy subjects. The data in this study 433 permit a 6-months assessment of Long-COVID-19 sequelae. Long-term prospective studies of 434 longer duration are still needed.

435

## 436 **5. Conclusions**

437 In the 6-months follow up Long COVID-19 cohort, among the tested parameters, those 438 positively correlated with comorbid conditions include age, BMI, D-dimers, NT-proBNP, C-439 reactive protein, neutrophils, fasting glucose, and HbA1c; hypertension also shows three 440 associations that were not found in patients when examining the role of diabetes: increased 441 hemoglobin, fibringen, and ferritin. In addition to hypertension and LV dysfunction, our study 442 found new cases of rhythm disturbances detected in 24-hour BP monitoring that included atrial 443 fibrillation (AF), AB block II degree, sinoatrial (SA) block, and RBBB. We speculate that due to 444 the significant association of hypertension with CT fibrotic changes, it may serve as an early 445 predictive marker (in combination with high Fbg and DD) for the development of lung 446 parenchymal diseases in post-COVID-19.

With the new outbreaks of SARS-CoV-2 infection in many countries, it is expected that the patients' burden having Long COVID-19 respiratory and cardiovascular sequelae is going to increase and lead to another public health crisis following the current pandemic. Thus, it is vital for further research comprising longer-ranging observational studies critical to evaluate the longterm consequences of COVID-19. The preliminary study presented here can be prolonged to 12 and 24 follow-ups. This will enable us to study the long-term effects of Long COVID-19 and identify symptoms significant for medical treatment and observation.

454

# 455 **References**

- 456 Abelmann WH. Virus and the heart. *Circulation* (1971) 44: 950-956.
- Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-*Nature* (2021) 594:259–64. http://dx.doi.org/10.1038/s41586-021-03553-9.
- Ali RMM, Ghonimy MBI. Post-COVID-19 pneumonia lung fibrosis: A worrisome sequelae in
  surviving patients. *Egypt. J. Radiol. Nucl. Med.* (2021) 52: 101. https://doi.org/10.1186/s43055021-00484-3.
- 462 Alraddadi BM, Watson JT, Almarashi A, Abedi GR, Turkistani A, et al. Risk factors for primary
  463 Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. *Emerging*
- 464 Infect. Dis. (2016) 22:49. doi: 10.3201/eid2201.151340.
- American College Cardiology. Coronavirus Disease 2019 (COVID-19) Provides Potent
  Reminder of the Risk of Infectious Agents. 2020. https://www.acc. org/latest-incardiology/articles/2020/03/01/08/42/ feature-coronavirus-disease-2019-covid-19providespotent-reminder-of-the-risk-of-infectious-agents.
- Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mulè G, Augello M, Mondatore D,
  Allegrini M, Cona A, Tesoro D. Female gender is associated with long COVID syndrome: a
  prospective cohort study. *Clinical Microbiol Infection* (2022) 28:611-e9.
  https://doi.org/10.1016/j.cmi.2021.11.002.
- Bichara CD, Amoras ES, Vaz GL, Bichara CN, Amaral IP, Vallinoto AC. Persistence of AntiSARS-CoV-2 IgM Antibody up to 8 Months Post-COVID-19. *Case Reports in Clinical Medicine* (2021), 10:227-31. DOI: 10.4236/crcm.2021.109029.
- 476 Cares-Marambio K, Montenegro-Jimenez Y, Torres-Castro R, et al. Prevalence of potential
  477 respiratory symptoms in survivors of hospital admission after coronavirus disease 2019
  478 (COVID-19): A systematic review and meta-analysis. *Chron Respir Dis.* (2021)
  479 18:14799731211002240.
- 480 Cheng L, Li H, Li L, Liu C, Yan S, Chen H, Li Y. Ferritin in the coronavirus disease 2019
- 481 (COVID 19): a systematic review and meta analysis. J Clin Laboratory Analysis (2020) 34:
  482 e23618. https://doi.org/10.1002/jcla.23618.
- 483 Chien YW, Liu ZH, Tseng FC, Ho TC, Guo HR, Ko NY, Ko WC, Perng GC. Prolonged 484 persistence of IgM against dengue virus detected by commonly used commercial assays. *BMC*
- 485 Infect Dis (2018) 18:1-7. https://doi.org/10.1186/s12879-018-3058-0.

- 486 Cuomo G, Puzzolante C, Iadisernia V, Santoro A, Menozzi M, et al. Development of post487 COVID-19 cardiovascular events: an analysis of clinical features and risk factors from a single
  488 hospital retrospective study. *UNIMORE IRIS* (2021) 2021: 538-549.
- 489 Das KM, Lee EY, Singh R, et al. Follow-up chest radiographic findings in patients with MERS490 CoV after recovery. *Indian J Radiol Imaging* (2017) 27:342–349. DOI:
  491 10.4103/ijri.IJRI\_469\_16.
- 492 de Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, De Souza FD et al. Severity and
- 493 mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a
  494 meta-analysis. *Diabetology & Metabolic Syndrome* (2020) 12:75 https://doi.org/10.1186/s13098495 020-00586-4.
- 496 de Boer RA, De Keulenaer G, Bauersachs J, Brutsaert D, Cleland JG et al. Towards better 497 definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the 498 Committee of Translational Research of the Heart Failure Association (HFA) of the European 499 Society of Cardiology. European Jof Heart Failure (2019)21:272-85. 500 https://doi.org/10.1002/ejhf.1406.
- 501Davido B, Seang S, Tubiana R, de Truchis P. Post-COVID-19 chronic symptoms: a502postinfectious entity?ClinMicrobiolInfect.(2020)26:1448-9.503https://doi.org/10.1016/j.cmi.2020.07.028.
- Deng Q, Hu B, Zhang Y, Wang H, et al. Suspected myocardial injury in patients with COVID19: Evidence from front-line clinical observation in Wuhan, China. *Int J Cardiol.* (2020) 311:
  116-121. https://doi.org/10.1016/j.ijcard.2020.03.087.
- Gao C, Cai Y. Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and
  antihypertensive treatment with COVID-19 mortality: a retrospective observational
  study. *European Heart J* (2020) 41: 2058-2066. https://doi.org/10.1093/eurheartj/ehaa433.
- Fabri L, Moss, S, Khan F, Chi W, Xia J. 2021. Post-viral parenchymal lung disease following
  COVID-19 hospitalization: a systematic review and meta-analysis. MedRxiv
  doi: https://doi.org/10.1101/2021.03.15.21253593 (Accepted, *Thorax*).
- 513 Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of 514 hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. *JAMA* 515 (2017) 317: 165–82. doi:10.1001/jama.2016.19043.
- 516 Fortini A, Torrigiani A, Sbaragli S, Lo Forte A, Crociani A, Cecchini P, et al. COVID-19: 517 persistence of symptoms and lung alterations after 3–6 months from hospital discharge. *Infection* 518 (2021) 49: 1007-1015. https://doi.org/10.1007/s15010-021-01638-1.
- 519 Fumagalli A, Misuraca C, Bianchi A, Borsa N, Limonta S, Maggiolini S et al. 2021 Long-term 520 changes in pulmonary function among patients surviving to COVID-19 pneumonia. *Infection* 521 (2021): 1-4. https://doi.org/10.1007/s15010-021-01718-2.
- 522 Furukawa NW, Brooks JT, Sobel J. Evidence supporting transmission of severe acute respiratory
- 523 syndrome coronavirus 2 while pre-symptomatic or asymptomatic. *Emerg Infect Dis* (2020) 26:
- 524 e201595. doi: 10.3201/eid2607.201595.

- 525 Gibney KB, Edupuganti S, Panella AJ, Kosoy OI, Delorey MJ, Lanciotti RS, Mulligan MJ,
- 526 Fischer M, Staples JE. Detection of anti-yellow fever virus immunoglobulin M antibodies at 3–4
- 527 years following yellow fever vaccination. *American J Tropical Med Hygiene* (2012) 87:1112.
- 528 Griffin I, Martin SW, Fischer M, Chambers TV, Kosoy OL, Goldberg C, Falise A, Villamil V,
- 529 Ponomareva O, Gillis LD, Blackmore C. Zika virus IgM 25 months after symptom onset, Miami-
- 530 Dade county, Florida, USA. *Emerging Infect Dis.* (2019) 25:2264. doi: 10.3201/eid2512.191022.
- 531 Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms
- and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med
- 533 *Virol* (2020) 2020:1–10. https://doi. org/10.1002/jmv.26368.
- Han H, Xie L, Liu R, et al. Analysis of heart injury laboratory parameters in 273 COVID-19
  patients in one hospital in Wuhan, China. J Med Virol. (2020) 92: 819-23.
  https://doi.org/10.1002/jmv.25809.
- Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. *BMJ* 333: 575 (2006). doi: https://doi.org/10.1136/bmj.38933.585764.AE.
- Hills SL, Van Keulen A, Feser J, Panella A, Letson GW, Staples JE, Marfin AA, Brault AC.
  Persistence of IgM antibodies after vaccination with live attenuated Japanese encephalitis
  vaccine. *American J Tropical Med Hygiene* (2021) 104:576. doi: 10.4269/ajtmh.20-1132.
- Holmes GP, Kaplan JE, Gantz NM, Komaroff, AL, Schonberger LB, et al. Chronic fatigue
  syndrome: a working case definition. *Annals Internal Med* (1988) 108:387-389.
  https://doi.org/10.7326/0003-4819-108-3-387.
- Hsia CC, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of
  inhaled insulin. *American J Medicine* (2005)118: 205-11.
  https://doi.org/10.1016/j.amjmed.2004.09.019.
- Huang AT, Garcia-Carreras B, Hitchings MD, Yang B, Katzelnick LC, et al. A systematic
  review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and
  association with severity. *Nature Comm* (2020) 11:1-6. https://doi.org/10.1038/s41467-02018450-4.
- Huang C, Huang L, Wang Y, Li X, Ren L, Gu X 6-month consequences of COVID-19 in
  patients discharged from hospital: a cohort study. *Lancet* (2021) 397:220-32.
  doi: http://dx.doi.org/10.1016/S0140-6736(20)32656-8.
- Jayedi A, Rahimi K, Bautista LE, Nazarzadeh M, Zargar MS, et al. Inflammation markers and
  risk of developing hypertension: a meta-analysis of cohort studies. *Heart* (2019) *105*: 686-692.
  doi: 10.1136/heartjnl-2018-314625.
- 559 Kao HW, Ashcavai M, Redeker AG. The persistence of hepatitis A IgM antibody after acute 560 clinical hepatitis A. *Hepatology* (1984) 4: 933-936. https://doi.org/10.1002/hep.1840040525.
- 561 Kapoor H, Signs K, Somsel P, Downes FP, Clark PA, Massey JP. Persistence of West Nile Virus
- 562 (WNV) IgM antibodies in cerebrospinal fluid from patients with CNS disease. *J Clin Virol* 563 (2004) 31:289-91. https://doi.org/10.1016/j.jcv.2004.05.017.

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of
hypertension: analysis of worldwide data. *Lancet* (2005) 365:217–23.
https://doi.org/10.1016/S0140-6736(05)17741-1.

567 Kreye J, Reincke SM, Prüss H. Do cross-reactive antibodies cause neuropathology in COVID-568 19? *Nat Rev Immunol.* (2020) 20:645-646. https://doi.org/10.1038/s41577-020-00458-y.

- 569 Lechowicz K, Drozd zal S, Machaj F, Rosik J, Szostak B et al. COVID-19: The potential
- 570 treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. *JCM* (2020) 9: 1917.
- 571 https://doi.org/10.3390/jcm9061917.
- Len P, Iskakova G, Sautbayeva Z, Kussanova A., Taeukelova AT et al. 2022. Meta-analysis and
  systematic review of coagulation disbalances in COVID-19: 41 studies and 17,601 patients. *Frontiers Cardiovascular Med* 9: 794092. doi: 10.3389/fcvm.2022.794092.
- 575 Lerner AM, Robinson DA, Yang L, et al. 2021. Toward understanding COVID-19 recovery:
- 576 National Institutes of Health workshop on postacute COVID-19. Ann Intern Med, 174: 999-
- 577 1003.
- 578 https://doi.org/10.7326/M21-1043.
- 579

580 Leth S, Gunst JD, Mathiasen V, Hansen K, Søgaard O, Østergaard L, Jensen-Fangel S, Storgaard 581 M, Agergaard J. Persistent symptoms in patients recovering from COVID-19 in Denmark. Open 582 Forum Infectious Dis (2021)8: ofab042). US: Oxford University Press. 583 https://doi.org/10.1093/ofid/ofab042.

584

Li Y, Li H, Zhu S, Xie Y, Wang B, He L, et al. Prognostic value of right ventricular longitudinal strain in patients with COVID-19. *Cardiovascular Imaging* (2020) 13:2287-2299. https://doi.org/10.1016/j.jcmg.2020.04.014.

Liang X, Shi L, Wang Y, Xiao W, Duan G, et al. The association of hypertension with the severity and mortality of COVID-19 patients: evidence based on adjusted effect estimates. *J. Infect.* (2020) 81: e44–e47. DOI: https://doi.org/10.1016/j.jinf.2020.06.060.

Long W, Yang J, Li Z, Li J, Chen S, Chen D, Wang S, Li Q, Hu D, Huang J, Zeng W. Abnormal
fibrinogen level as a prognostic Indicator in coronavirus disease patients: a retrospective cohort
study. *Frontiers in Med.* (2021) 8:687220. doi: 10.3389/fmed.2021.687220.

594 Madhur MS, Elijovich F, Alexander MR, Pitzer A, Ishimwe J, et al. Hypertension. Do 595 inflammation and immunity hold the key to solving this epidemic? *Circ Res* (2021) 128: 908-596 933. DOI: 10.1161/CIRCRESAHA.121.318052.

Mallon PW, Tinago W, Leon AG, McCann K, Kenny G, et al. Dynamic change and clinical
relevance of postinfectious SARS-CoV-2 antibody responses. In: *Open Forum Infectious Diseases* (2021) 8: ofab122. US, Oxford University Press. https://doi.org/10.1093/ofid/ofab122.

Mancia, G., Rea, F., Ludergnani, M., Apolone, G. & Corrao, G. Renin – angiotensin–aldosterone
system blockers and the risk of Covid-19. *N. Engl. J. Med.* (2020) 382: 2431–2440. DOI:
10.1056/NEJMoa2006923.

Medranda GA, Fazlalizadeh H, Case BC, Yerasi C, Zhang C, et al. 2021. Implications of left ventricular function on short-term outcomes in COVID-19 patients with myocardial

605injury. CardiovascularRevascularizationMed(2021)29:45-49.606https://doi.org/10.1016/j.carrev.2021.03.028.

Mineo G, Ciccarese F, Modolon C, Landini MP, Valentino M, Zompatori M. Post-ARDS
pulmonary fibrosis in patients with H1N1 pneumonia: role of follow-up CT. *Radiol Med*(*Torino*) (2012) 117:185–200. https://doi.org/10.1007/s11547-011-0740-3.

610 Mohammad M, Emin M, Bhutta A, Gul EH, Voorhees E, Afzal MR. Cardiac arrhythmias 611 associated with COVID-19 infection: state of the art review. *Expert Rev Cardiovascular Therapy* 612 (2021) 10: 881 880 https://doi.org/10.1080/14770072.2021.1007580

612 (2021), 19: 881-889. https://doi.org/10.1080/14779072.2021.1997589.

613 Murray KO, Garcia MN, Yan C, Gorchakov R. Persistence of detectable immunoglobulin M 614 antibodies up to 8 years after infection with West Nile virus. *American J Tropical Med Hygiene* 615 (2013) 89:996. doi: 10.4269/ajtmh.13-0232.

616 Naik, P.K., Moore, B.B. Viral infection and aging as cofactors for the development of pulmonary 617 fibrosis. *Expert Rev Respiratory Med* (2010) 4: 759-771. https://doi.org/10.1586/ers.10.73.

618 Nalvsnyk L. Hernandez-Medina M. Krishnarajah G. Glycaemic variability and complications in

619 patients with diabetes mellitus: evidence from a systematic review of the literature. *Diabetes* 

620 *Obes Metab* (2010) 12:288-298. https://doi.org/10.1111/j.1463-1326.2009.01160.x.

Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent
symptoms among patients with COVID-19: a systematic review. *JAMA network open*.
2021;4(5): e2111417. doi: http://dx.doi.org/10.1001/jamanetworkopen.2021.11417.

Nehme M, Braillard O, Alcoba G, Aebischer Perone S, Courvoisier D, Chappuis F. COVID-19
symptoms: longitudinal evolution and persistence in outpatient settings. *Ann Intern Med.*(2021)174(5):723-5. doi: http://dx.doi.org/10.7326/M20-5926.

Navarro AO, Cervantes-Bojalil J, Quevedo ODJC, Martínez AA, Hernández-Jiménez CA, et al.
 Decreased quality of life and spirometric alterations even after mild-moderate COVID-19. *Respir Med.* (2021) 181:106391. https://doi.org/10.1016/j.rmed.2021.106391.

Pranata R, Lim MA. Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased
mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis
and meta-regression. *J Renin-Angiotensin-Aldosterone System: JRAAS* (2020) 21:
1470320320926899.

Raafs AG, Verdonschot JA, Henkens MT, Adriaans BP, Wang P et al. The combination of
carboxy□terminal propeptide of procollagen type I blood levels and late gadolinium
enhancement at cardiac magnetic resonance provides additional prognostic information in
idiopathic dilated cardiomyopathy–A multilevel assessment of myocardial fibrosis in dilated
cardiomyopathy. *European J Heart Failure* (2021) 23:933-44. https://doi.org/10.1002/ejhf.2201.

Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of
COVID-19 with a cardiovascular focus. *European Heart J*. (2022) 43:1157-1172.
https://doi.org/10.1093/eurheartj/ehac031.

Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, Lanciotti RS, Campbell GL.
Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus
encephalitis cases. *Emerging Infectious Dis.* (2003) 9:376. doi: 10.3201/eid0903.020531.

- 645 Sandler M. Is the lung a 'target organ' in diabetes mellitus? *Arch Intern Med* (1990) 150: 1385646 1388. doi:10.1001/archinte.1990.00390190051006.
- 647 Satterfield BA, Bhatt DL, Gersh BJ. Cardiac involvement in the long-term applications of 648 COVID-19. *Nature Rev Cardiology* (2022) 19: 332-341. https://doi.org/10.1038/s41569-021-
- 649 00631-3.
- 650 Štěpánek L, Janošíková M, Štěpánek L, Nakládalová M, Boriková A. The kinetics and predictors
- 651 of anti SARS CoV 2 antibodies up to 8 months after symptomatic COVID 19: A Czech
- 652 cross □ sectional study. *J Medical Virol* (2022) EPub Apr 14. https://doi.org/10.1002/jmv.27784.
- 653 Shah W, Hillman T, Playford ED, et al. Managing the long-term effects of Covid-19: summary 654 SIGN. rapid guideline. of NICE. and RCGP BMJ (2021)372: n136. 655 doi: https://doi.org/10.1136/bmj.n136.
- 656 Shi H, Han X, Jiang N, Cao Y, Alwalid O, et al. Radiological findings from 81 patients with
- 657 COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infectious Dis. (2020)
- 658 20:425-34. https://doi.org/10.1016/S1473-3099(20)30086-4.
- Shieh W-JBD, Blau DM, Denison AM, et al. 2009 pandemic influenza A (H1N1): pathology and
  pathogenesis of 100 fatal cases in the United States. *Am J Pathol* (2010) 177:166–175.
  https://doi.org/10.2353/ajpath.2010.100115.
- CO Sinch AV Sinch D Harvestermite with set disheter and new
- Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated
  with poorer outcomes in COVID-19. *Diabetes Res. Clinical Practice* (2020) 167:108382.
  https://doi.org/10.1016/j.diabres.2020.108382.
- Solomon JJ, Heyman B, Ko JP, Condos R, Lynch DA. CT of post-acute lung complications of
  COVID-19. *Radiology* (2021) 2021: 211396. doi: 10.1148/radiol.2021211396.
- Suthahar N, Meijers WC, Silljé HH, de Boer RA. From inflammation to fibrosis—molecular and
  cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment
  opportunities. *Current* Heart Failure Reports (2017) 14:235-250.
  https://doi.org/10.1007/s11897-017-0343-y.
- Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. *Front Immunol* (2020) 11: 1708. doi: 10.3389/fimmu.2020.01708.
- Tartari CJ, Milani G, Salvetti F, Marchetti M, Russo L, Vignoli A, Vitali M, Schieppati F,
  Ravasio G, Castellani L, Sanga E. Post-Covid-19 hemostatic characteristics of convalescent
  patients: The Bergamo Experience. *Blood* (2021)138(Suppl. 1):1054.
  https://doi.org/10.1182/blood-2021-153611.
- Trump S, Lukassen S, Anker MS, Chua RL, Liebig J. et al. 2021. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. *Nature Biotechnol.* (2021) 39:705-716. https://doi.org/10.1038/s41587-020-00796-1.
- 680 Tudoran C, Tudoran M, Cut TG, Lazureanu VE, Oancea C, et al. Evolution of echocardiographic
- abnormalities identified in previously healthy individuals recovering from COVID-19. J
   *Personalized Med* (2022) 12:46. https://doi.org/10.3390/jpm12010046.

Vojdani A, Monro J, Lanzisera F, Sadeghi H. Serological cross-reactivity between viruses and
their contribution to autoimmunity. *Autoimmunity Rev.* (2021) 7:102840.
DOI: 10.1016/j.autrev.2021.102840.

- Wang JY, Chang SY, Huang YW, Chang SC. Serology-positive but minimally symptomatic
  COVID-19 may still cause lung injury and lung function impairment. *Int J Tuberc Lung Dis.*(2020) 24:568-569. doi: 10.5588/ijtld.20.0197.
- Wu Q, Zhong L, Li H, Guo J, Li Y, Hou X, et al. A follow-up study of lung function and chest
  computed tomography at 6 months after discharge in patients with coronavirus disease 2019. *Can Respir J.* (2021) 2021:6692409. https://doi.org/10.1155/2021/6692409.
- Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, et al. Plasma glucose levels and diabetes are
  independent predictors for mortality and morbidity in patients with SARS. *Diabetic Med.* (2006)
  23:623-8. https://doi.org/10.1111/j.1464-5491.2006.01861.x.
- Yang J, Xue Q, Miao L, Cai L. Pulmonary fibrosis: a possible diabetic complication. *Diabetes/Metabolism Research and Rev.* (2011) 27:311-317. https://doi.org/10.1002/dmrr.1175.
- 697 Young SJ. Long-COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors 698 and treatments. *Infect Dis.* (2021) 53: 737-754. https://doi.org/10.1080/23744235.2021.1924397.
- Zhang P, Li J, Liu H, Han N, Ju J, et al. Correction: Long-term bone and lung consequences
  associated with hospital-acquired severe acute respiratory syndrome: A 15-year follow-up from a
  prospective cohort study. *Bone Res.* (2020) 8: 1-8. https://doi.org/10.1038/s41413-020-0084-5.
- Zhao Y-M, Shang Y-M, Song W-B, et al. Follow-up study of the pulmonary function and related
   physiological characteristics of COVID-19 survivors three months after recovery.
   *EClinicalMedicine* (2020) 25:100463. https://doi.org/10.1016/j.eclinm.2020.100463.
- Zhou M, Wong C, Un K, Lau Y, Lee J, Tam F, et al. Cardiovascular sequalae in uncomplicated
  COVID-19 survivors. *PLoS ONE* (2021) 16: e0246732. doi:10.1371/journal.pone.0246732.
- 707

# 708 Acknowledgements

- 709 This research has been funded by the Science Committee of the Ministry of Education and
- 710 Science of the Republic of Kazakhstan (Grant No. BR10965164). https://www.ncste.kz/en/main.
- The funders had no role in study design, data collection and analysis, decision to publish, or
- 712 preparation of the manuscript.

## 713 Authors' contributions

- 714 AT, ZK, BA, NK, MB Conceptualization, Investigation, Methodology, Supervision, Writing -
- 715 review & editing, AS, SK Data curation, project administration. ZS, PL Methodology,
- 716 Statistical analysis. NSB Supervision, Analysis, Writing a draft. All authors read and edit a
- 717 final draft. All authors contributed to the article and approved the submitted version.

## 718 **Competing interests**

719 The authors declare no competing financial interests.

## 720 Data Availability Statement

721 There is a risk of identification of sensitive data of individual patients due to small subgroups;

- therefore, the data are not openly accessible on request.
- 723
- 724
- 725

## 726 Abbreviations

BMI – body mass index; CAD – coronary artery disease; COPD – chronic obstructive pulmonary
disease; CRP – C-reactive protein; CMV – cytomegalovirus; CT – computer tomography; DBP –
low diastolic blood pressure; DD – D-dimer; Fbg – fibrinogen; GI disorders – gastrointestinal
disorders; HbA1c - glycohemoglobin A1c; LV - Left ventricular; 6MWT – six minute test; NTproBNP - ventricular natriuretic peptide; RBBB – right bundle branch block; SA – sinoatrial;
SBP – systolic blood pressure

732 733

## 734 Legends to Tables

735 **Table 1.** Clinical characteristic and comorbidities in participants after COVID-19 infection.

**Table 2.** Participants-reported clinical manifestations persistent after COVID-19 infection at
 median of 6 months follow-up.

738 **Table 3.** Cardiac abnormalities detected in cardiac assessment of post-COVID-19 patients.

**Table 4.** Laboratory results of blood sample in participants after COVID-19 infection withmedian follow-up of 6 months.

741

# 742 Legends to the Figures

743 **Figure 1.** Study flow diagram.

744 Figure 2. Clinical characteristics and laboratory results of blood samples in post-COVID-19

745 patients with and without type 2 diabetes: age, D-dimers (DD), ventricular natriuretic peptide

- 746 (NT-proBNP), C-reactive protein (CRP), body mass index (BMI), neutrophils, fasting glucose 747 and glycated hemoglobin (HbA1c) (\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001).
- **Figure 3.** Clinical characteristics and laboratory results of blood samples in post-COVID-19
- patients with and without hypertension: age, BMI, NT-pro BNP, CRP, neutrophils, white blood

- cells (WBC), DD, fasting glucose, HbA1c, HGB, fibrinogen and ferritin (\*p < 0.05, \*\*p < 0.01, \*\*\*\*p < 0.0001).
- **Figure 4.** Clinical characteristics and laboratory results of blood samples in post-COVD-19 patients with no comorbidities (green), Hypertension only (blue), type 2 diabetes mellitus only (orange) and both hypertension and type 2 diabetes mellitus (red): age, BMI, NT-proBNP, CRP, neutrophils, WBC, DD, fasting glucose, HbA1c, HGB, fibrinogen and ferritin (\*\*p < 0.01, \*\*\*p< 0.001, \*\*\*\*p < 0.0001).
- 757 Figure 5. Fibrotic changes in CT scan of post-COVID-19 patients with Hypertension (A).
- 758 Cardiac abnormalities in post-COVID-19 patients with and without hypertension (**B**); with and
- 759 without type 2 (C). (\*p < 0.05, \*\*\*p < 0.001, \*\*\*\*p < 0.0001).
- 760

#### 761 Supplemental Data

Appendix 1. Results of a questionnaire with items on demographic information, current
 complaints, comorbidities, and medications.

- 764 Appendix 2. Results of a Chalder Fatigue Scale (CFS) questionnaire.
- 765 Appendix 3. CT abnormalities.